Timothy Graham, MD
Endocrinology, Diabetes & Metabolism · Sandy, UTNPI 1134162258
Payments from drug & device makers
Across 862 payments — averaging $628.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sequel Med Tech, LLC$205K
- Tandem Diabetes Care, Inc.$110K
- Eli Lilly$74K
- Novo Nordisk$46K
- Ascendis Pharma Endocrinology Inc$37K
- Novartis$34K
- plus $35K from 49 others
Across 6 payments — averaging $8123.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$40K
- Novartis$9K
What the payments were for
- Consulting fees$10,92912%
- Speaking & faculty fees$64,76872%
- Travel & lodging$4,0214%
- Food & beverage$9,99411%
- Education$5911%
- Entertainment$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$27,183
- Tresiba$9,435
- t-slim insulin pump$9,350
- Xultophy 100/3.6$7,480
- Omnipod$2,005
- t:slim X2 insulin pump$1,050
- LEQVIO$500
- MYCAPSSA$325
- TWIIST$234
- TZIELD$231
- SKYTROFA$129
- Yorvipath$122
How this compares
$541,353 in reported general payments places this provider in the 90th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 204 | $254,960 |
| OzempicSemaglutide | 141 | $201,720 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 146 | $200,697 |
| SamscaTolvaptan | 12 | $175,345 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 106 | $151,284 |
| TrulicityDulaglutide | 83 | $119,023 |
| JardianceEmpagliflozin | 96 | $115,781 |
| FarxigaDapagliflozin Propanediol | 99 | $93,447 |
| Somatuline DepotLanreotide Acetate | 11 | $91,134 |
| ForteoTeriparatide | 12 | $59,779 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $58,947 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $54,306 |
| Xigduo XrDapaglifloz Propaned/Metformin | 44 | $49,754 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 31 | $41,449 |
| KerendiaFinerenone | 34 | $40,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro | $557 | $446,519354 claims |
| Novo NordiskOzempic, Novolog | $46,458 | $210,120166 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $5,618 | $200,697146 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $205 | $151,754127 claims |
| AstraZenecaFarxiga | $253 | $93,44799 claims |
| BayerKerendia | $67 | $40,30934 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $5,415468 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
Other endocrinology, diabetes & metabolism in Sandy
- Amnon SchlegelSandy$57K
- Richard CannonSandy$5K
- Jack WahlenOgden$1.5M
- Eliot BrintonSalt Lake City$822K
- Claudia FishPark City$286K
- Alireza Falahati-NiniSalt Lake City$251K
- Steven BrownLayton$105K
- Mohammed NizamProvo$54K
- Debra SimmonsSalt Lake City$36K
- James GruaWest Valley City$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.